Yan and Ansun Biopharma have reached a strategic partnership on the development and production of the biopharmaceaser CMC.

Introduction: Ansun Biopharma ("Ansun"), a clinical biopharmaceutical company in the United States, has been announced.
/ Hangzhou, August 27, 2020 /Agency/ -- Ansun Biopharma ("Ansun"), a biopharmaceutical contract development and production company focused on providing quality, reliable and rapid service to partners, today announced a strategic partnership with Ansun Biopharma ("Ansun"), a clinical biopharmaceutical company in the United States, to provide CMC development and production services for its biopharmaceutical research and development pipeline.
project is expected to be submitted in 2021.
Over the next three years, an all-process CMC service from cell line development, process development, preparation development to GMP production, IND data writing, and clinical and commercial production worldwide will be provided to Ansun with comprehensive expertise in accordance with the cooperation agreement.
Wang, Chief Technology Officer of Sansun, said, "We are very pleased to have reached a strategic partnership with Angziz.
to us, this partnership is an important guarantee for Sansun to achieve its development goals and one of the key foundations for advancing the biopharmace technology pipeline in the coming years.
As more early-stage research and development products enter clinical development, product pipelines continue to expand, and working with reliable and powerful CDMO companies like Yan'an Jishi can help us quickly turn promising scientific research into clinical applications for the benefit of patients around the world.
Yang Xiaoming, General Manager of Ansun, said, "We are proud to be Ansun's CMC development and production partner to support its fast and high-quality innovative biopharmaceuser projects.
-class and robust supply chain is the basis for the rapid and successful marketability of biotechnology.
the impact of recent outbreaks on global drug development and production capacity, companies are more eager to stay focused and agile while achieving much-needed capacity.
as a CDMO-focused company, we will continue to create value and empower our partners at home and abroad to provide better treatment for our patients.
" has undertaken more than 20 CDMO projects from multiple partners since it started production in 2018, and has successfully delivered nearly 30 batches of GMP products, which have been successfully clinically approved by the Pharmaceutical Regulatory Departments in China and the United States, respectively.
with high-quality, reliable and fast service, we have been recognized by partners.
To this day, Yan Anzishi has complete CMC capabilities such as cell line development, cell bank establishment, process and preparation development, technology transfer and optimization, GMP production, and currently has 3 raw liquid production lines (500-2,000L) and 1 preparation filling line.
In the first half of 2020, the company not only minimized the impact of the new crown pneumonia outbreak, but also more than doubled the number of customer projects it d'athons, demonstrating its outstanding execution, delivery capacity and quality system.
.